JP2019519524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519524A5 JP2019519524A5 JP2018561516A JP2018561516A JP2019519524A5 JP 2019519524 A5 JP2019519524 A5 JP 2019519524A5 JP 2018561516 A JP2018561516 A JP 2018561516A JP 2018561516 A JP2018561516 A JP 2018561516A JP 2019519524 A5 JP2019519524 A5 JP 2019519524A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- folate receptor
- bone marrow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 210000001185 bone marrow Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 102000006815 folate receptor Human genes 0.000 claims 4
- 108020005243 folate receptor Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 102000010449 Folate receptor beta Human genes 0.000 claims 2
- 108050001930 Folate receptor beta Proteins 0.000 claims 2
- 102000002689 Toll-like receptor Human genes 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 claims 1
- ADVCGXWUUOVPPB-XLPZGREQSA-N 1-[(2r,4s,5s)-4-amino-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N)C1 ADVCGXWUUOVPPB-XLPZGREQSA-N 0.000 claims 1
- QIBKIAFNCVIIMG-UHFFFAOYSA-N 10,20-diphenyl-21,22-dihydroporphyrin Chemical compound C1=CC(C(=C2C=CC(N2)=CC2=CC=C3N2)C=2C=CC=CC=2)=NC1=CC(=N1)C=CC1=C3C1=CC=CC=C1 QIBKIAFNCVIIMG-UHFFFAOYSA-N 0.000 claims 1
- SWELIMKTDYHAOY-UHFFFAOYSA-N 2,4-diamino-6-hydroxypyrimidine Chemical compound NC1=CC(=O)N=C(N)N1 SWELIMKTDYHAOY-UHFFFAOYSA-N 0.000 claims 1
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 229940122255 Microtubule inhibitor Drugs 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000013968 STAT6 Transcription Factor Human genes 0.000 claims 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 claims 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 1
- 229950006418 dactolisib Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341587P | 2016-05-25 | 2016-05-25 | |
| US62/341,587 | 2016-05-25 | ||
| PCT/US2017/034537 WO2017205661A1 (en) | 2016-05-25 | 2017-05-25 | Method of treating cancer by targeting myeloid-derived suppressor cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519524A JP2019519524A (ja) | 2019-07-11 |
| JP2019519524A5 true JP2019519524A5 (cg-RX-API-DMAC7.html) | 2020-07-02 |
| JP7278777B2 JP7278777B2 (ja) | 2023-05-22 |
Family
ID=60412652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561516A Active JP7278777B2 (ja) | 2016-05-25 | 2017-05-25 | 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190216935A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3463367A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7278777B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102489277B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109475558A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017271550B2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL263059B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017205661A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019317278B2 (en) * | 2018-08-07 | 2025-05-22 | Purdue Research Foundation | Rejuvenation of CAR T cell |
| CN114269346A (zh) * | 2019-07-08 | 2022-04-01 | 普渡研究基金会 | 用于治疗和预防纤维化疾病状态和癌症的化合物和方法 |
| AU2021305193A1 (en) * | 2020-07-08 | 2023-02-09 | Purdue Research Foundation | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer |
| EP4271378A4 (en) * | 2021-01-04 | 2026-03-11 | Purdue Research Foundation | METHODS FOR IMPROVING MODIFIED CELL THERAPIES IN CANCER TREATMENT |
| CN118829726A (zh) | 2022-03-08 | 2024-10-22 | 科纳斯特股份有限公司 | 包含胶原酶、钙、组氨酸及甘氨酸的组合物及胶原酶的稳定化方法 |
| CN116283709A (zh) * | 2023-01-13 | 2023-06-23 | 华中科技大学同济医学院附属同济医院 | 一种脂滴包被蛋白3的抑制剂及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2470668C2 (ru) | 2005-08-19 | 2012-12-27 | Эндосайт, Инк. | Конъюгаты лиганда с несколькими лекарственными средствами |
| US20120128587A1 (en) * | 2009-07-31 | 2012-05-24 | Endocyte, Inc. | Folate-targeted diagnostics and treatment |
| CA2793657A1 (en) * | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| WO2012149416A2 (en) * | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013082591A1 (en) * | 2011-12-02 | 2013-06-06 | University Of South Florida | Compositions and methods for modulating myeloid derived suppressor cells |
| WO2013169913A1 (en) * | 2012-05-08 | 2013-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Predictors of patient response to interferon-a therapy |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| EA201590622A1 (ru) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения |
| WO2014201245A1 (en) * | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
| CN106456628A (zh) * | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| EP3215844B1 (en) * | 2014-08-19 | 2021-04-28 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs) |
| EP3223860A4 (en) * | 2014-11-25 | 2018-08-01 | Endocyte, Inc. | Methods of treating cancer by targeting tumor-associated macrophages |
| CN107847609A (zh) | 2015-03-13 | 2018-03-27 | 恩多塞特公司 | 用于治疗疾病的缀合物 |
-
2017
- 2017-05-25 CN CN201780046536.9A patent/CN109475558A/zh active Pending
- 2017-05-25 IL IL263059A patent/IL263059B2/en unknown
- 2017-05-25 CN CN202210697024.1A patent/CN114903890A/zh active Pending
- 2017-05-25 AU AU2017271550A patent/AU2017271550B2/en active Active
- 2017-05-25 WO PCT/US2017/034537 patent/WO2017205661A1/en not_active Ceased
- 2017-05-25 JP JP2018561516A patent/JP7278777B2/ja active Active
- 2017-05-25 KR KR1020187037409A patent/KR102489277B1/ko active Active
- 2017-05-25 US US16/302,912 patent/US20190216935A1/en active Pending
- 2017-05-25 EP EP17803611.7A patent/EP3463367A4/en active Pending
-
2021
- 2021-02-03 US US17/166,759 patent/US20210170035A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Porter et al. | Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy | |
| JP2016501221A5 (cg-RX-API-DMAC7.html) | ||
| Amiri-Kordestani et al. | Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies | |
| JP2016533366A5 (cg-RX-API-DMAC7.html) | ||
| JP2016514689A5 (cg-RX-API-DMAC7.html) | ||
| JP2016523974A5 (cg-RX-API-DMAC7.html) | ||
| JP2009514880A5 (cg-RX-API-DMAC7.html) | ||
| JP2015508103A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528246A5 (cg-RX-API-DMAC7.html) | ||
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
| JP2009514881A5 (cg-RX-API-DMAC7.html) | ||
| JP2019518765A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512398A5 (cg-RX-API-DMAC7.html) | ||
| PH12015500212A1 (en) | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoixoindolin-2-yl)piperidine-2,6-dione | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| JP2017503850A5 (cg-RX-API-DMAC7.html) | ||
| JP2010522194A5 (cg-RX-API-DMAC7.html) | ||
| WO2009007751A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| JP2016538344A5 (cg-RX-API-DMAC7.html) | ||
| JP2011515397A5 (cg-RX-API-DMAC7.html) | ||
| RU2015125307A (ru) | Комбинированная терапия | |
| JP2015509540A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512943A5 (cg-RX-API-DMAC7.html) | ||
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |